STRASBOURG, France--Paul Berg, director of the Beckman Center for Molecular and Genetic Research at Stanford University School of Medicine, and G. Steven Burrill, CEO of Burrill & Company, a private merchant bank specializing in life sciences companies, have joined the board of directors at integrated biotech firm Transgene here.
Winner of the Nobel Prize for chemistry in 1980 for his studies of the biochemistry of nucleic acids with a specific emphasis on recombinant DNA, Berg will also participate in meetings of Transgene's scientific board.
Transgene is dedicated to the discovery and development of gene therapy technologies and products for the treatment of acquired or inherited diseases for which there is no cure or adequate therapy.